- Home
- CRGX vs JRS Comparison
CRGX vs JRS Comparison
Compare CRGX & JRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- JRS
- Stock Information
- Founded
- CRGX 2021
- JRS 2001
- Country
- CRGX United States
- JRS United States
- Employees
- CRGX N/A
- JRS N/A
- Industry
- CRGX
- JRS Finance/Investors Services
- Sector
- CRGX
- JRS Finance
- Exchange
- CRGX Nasdaq
- JRS Nasdaq
- Market Cap
- CRGX 213.5M
- JRS 224.5M
- IPO Year
- CRGX 2023
- JRS N/A
- Fundamental
- Price
- CRGX $4.52
- JRS $7.90
- Analyst Decision
- CRGX Hold
- JRS
- Analyst Count
- CRGX 7
- JRS 0
- Target Price
- CRGX $5.33
- JRS N/A
- AVG Volume (30 Days)
- CRGX 3.0M
- JRS 86.6K
- Earning Date
- CRGX 08-11-2025
- JRS 01-01-0001
- Dividend Yield
- CRGX N/A
- JRS 8.87%
- EPS Growth
- CRGX N/A
- JRS N/A
- EPS
- CRGX N/A
- JRS N/A
- Revenue
- CRGX N/A
- JRS N/A
- Revenue This Year
- CRGX $57.81
- JRS N/A
- Revenue Next Year
- CRGX N/A
- JRS N/A
- P/E Ratio
- CRGX N/A
- JRS N/A
- Revenue Growth
- CRGX N/A
- JRS N/A
- 52 Week Low
- CRGX $3.00
- JRS $5.95
- 52 Week High
- CRGX $25.45
- JRS $8.00
- Technical
- Relative Strength Index (RSI)
- CRGX 54.72
- JRS 54.16
- Support Level
- CRGX $4.40
- JRS $7.80
- Resistance Level
- CRGX $4.63
- JRS $8.10
- Average True Range (ATR)
- CRGX 0.07
- JRS 0.11
- MACD
- CRGX -0.01
- JRS 0.02
- Stochastic Oscillator
- CRGX 34.29
- JRS 47.37
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.
About JRS Nuveen Real Estate Income Fund of Beneficial Interest
Nuveen Real Estate Income Fund is a diversified closed-end investment company. The Fund invests primarily in income-producing common stocks, preferred stocks, convertible preferred stocks, and debt securities issued by real estate companies.